EdgarLookup

TANDEM DIABETES CARE INC — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that TANDEM DIABETES CARE INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $249.25M Nov 6, 2025
Q2 2025 Jun 30, 2025 $240.68M Aug 6, 2025
Q1 2025 Mar 31, 2025 $234.42M Apr 30, 2025
Q3 2025 Sep 30, 2024 $243.97M Nov 6, 2025
Q2 2025 Jun 30, 2024 $221.91M Aug 6, 2025
Q1 2025 Mar 31, 2024 $191.67M Apr 30, 2025
Q3 2024 Sep 30, 2023 $185.62M Nov 6, 2024
Q2 2024 Jun 30, 2023 $195.92M Aug 1, 2024
Q1 2024 Mar 31, 2023 $169.38M May 2, 2024
Q3 2023 Sep 30, 2022 $204.55M Nov 1, 2023
Q2 2023 Jun 30, 2022 $200.26M Aug 3, 2023
Q1 2023 Mar 31, 2022 $175.91M May 3, 2023
Q3 2022 Sep 30, 2021 $179.63M Nov 2, 2022
Q2 2022 Jun 30, 2021 $172.14M Aug 3, 2022
Q1 2022 Mar 31, 2021 $141.04M May 4, 2022
Q3 2021 Sep 30, 2020 $123.60M Nov 3, 2021
Q2 2021 Jun 30, 2020 $109.24M Aug 4, 2021
Q1 2021 Mar 31, 2020 $97.93M May 5, 2021
Q3 2020 Sep 30, 2019 $94.66M Nov 5, 2020
Q2 2020 Jun 30, 2019 $93.26M Jul 30, 2020

Revenue (Net Sales) — By Quarter

Quarter Fiscal Year Period End Value Filed
Q1 2018 Mar 31, 2018 $27.28M Apr 26, 2018
Q3 2017 Sep 30, 2017 $27.00M Oct 26, 2017
Q2 2017 Jun 30, 2017 $21.33M Jul 27, 2017
Q1 2018 Mar 31, 2017 $18.98M Apr 26, 2018
Q3 2017 Sep 30, 2016 $12.29M Oct 26, 2017
Q2 2017 Jun 30, 2016 $22.99M Jul 27, 2017
Q1 2017 Mar 31, 2016 $20.06M Apr 27, 2017
Q3 2016 Sep 30, 2015 $15.72M Nov 1, 2016
Q2 2016 Jun 30, 2015 $15.71M Jul 28, 2016
Q1 2016 Mar 31, 2015 $12.31M Apr 28, 2016
Q3 2015 Sep 30, 2014 $13.51M Oct 29, 2015
Q2 2014 Jun 30, 2014 $10.25M Jul 31, 2014
Q1 2015 Mar 31, 2014 $8.07M Apr 30, 2015
Q3 2014 Sep 30, 2013 $7.78M Nov 6, 2014
Q2 2014 Jun 30, 2013 $5.53M Jul 31, 2014
Q1 2014 Mar 31, 2013 $5.46M May 6, 2014

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($21.17M) Nov 6, 2025
Q2 2025 Jun 30, 2025 ($52.40M) Aug 6, 2025
Q1 2025 Mar 31, 2025 ($130.56M) Apr 30, 2025
Q3 2025 Sep 30, 2024 ($23.25M) Nov 6, 2025
Q2 2025 Jun 30, 2024 ($30.81M) Aug 6, 2025
Q1 2025 Mar 31, 2024 ($42.72M) Apr 30, 2025
Q3 2024 Sep 30, 2023 ($32.96M) Nov 6, 2024
Q2 2024 Jun 30, 2023 ($35.78M) Aug 1, 2024
Q1 2024 Mar 31, 2023 ($123.87M) May 2, 2024
Q3 2023 Sep 30, 2022 ($48.97M) Nov 1, 2023
Q2 2023 Jun 30, 2022 ($15.06M) Aug 3, 2023
Q1 2023 Mar 31, 2022 ($14.72M) May 3, 2023
Q3 2022 Sep 30, 2021 $5.79M Nov 2, 2022
Q2 2022 Jun 30, 2021 $4.01M Aug 3, 2022
Q1 2022 Mar 31, 2021 ($5.04M) May 4, 2022
Q3 2021 Sep 30, 2020 ($9.41M) Nov 3, 2021
Q2 2021 Jun 30, 2020 ($27.11M) Aug 4, 2021
Q1 2021 Mar 31, 2020 ($14.87M) May 5, 2021
Q3 2020 Sep 30, 2019 ($2.90M) Nov 5, 2020
Q2 2020 Jun 30, 2019 ($1.51M) Jul 30, 2020

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($22.86M) Nov 6, 2025
Q2 2025 Jun 30, 2025 ($51.81M) Aug 6, 2025
Q1 2025 Mar 31, 2025 ($120.88M) Apr 30, 2025
Q3 2025 Sep 30, 2024 ($26.09M) Nov 6, 2025
Q2 2025 Jun 30, 2024 ($30.77M) Aug 6, 2025
Q1 2025 Mar 31, 2024 ($41.68M) Apr 30, 2025
Q3 2024 Sep 30, 2023 ($31.55M) Nov 6, 2024
Q2 2024 Jun 30, 2023 ($38.81M) Aug 1, 2024
Q1 2024 Mar 31, 2023 ($127.82M) May 2, 2024
Q3 2023 Sep 30, 2022 ($47.49M) Nov 1, 2023
Q2 2023 Jun 30, 2022 ($12.24M) Aug 3, 2023
Q1 2023 Mar 31, 2022 ($15.34M) May 3, 2023
Q3 2022 Sep 30, 2021 $7.72M Nov 2, 2022
Q2 2022 Jun 30, 2021 $5.43M Aug 3, 2022
Q1 2022 Mar 31, 2021 ($3.24M) May 4, 2022
Q3 2021 Sep 30, 2020 ($1.01M) Nov 3, 2021
Q2 2021 Jun 30, 2020 ($12.04M) Aug 4, 2021
Q1 2021 Mar 31, 2020 ($13.57M) May 5, 2021
Q3 2020 Sep 30, 2019 ($6.00M) Nov 5, 2020
Q2 2020 Jun 30, 2019 ($1.87M) Jul 30, 2020